Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AKTX Akari Therapeutics PLC

休市中 08-21 16:00:00 EDT

7.85

+0.06

+0.77%

盘后7.85

+0.000.00%

19:30 EDT

最高8.10	最低7.70	成交量1.10万
今开8.10	昨收7.79	日振幅5.13%
总市值1,528万	流通市值545.18万	总股本194.70万
成交额8.70万	换手率1.58%	流通股本69.45万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AKTX","market":"US","secType":"STK","nameCN":"Akari Therapeutics PLC","latestPrice":7.85,"timestamp":1787342400000,"preClose":7.79,"halted":0,"volume":10988,"hourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":7.85,"latestTime":"19:30 EDT","volume":56,"amount":444.14,"timestamp":1787355004937,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0077021822849806946,"floatShares":694500,"shares":1947000,"eps":-16.023678,"marketStatus":"休市中","change":0.06,"latestTime":"08-21 16:00:00 EDT","open":8.095,"high":8.1,"low":7.7,"amount":86959.91104,"amplitude":0.051348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-16.023678,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":1,"adrRate":2000,"exchange":"NASDAQ","adjPreClose":7.79,"preHourTrading":{"tag":"盘前","latestPrice":7.7033,"preClose":7.79,"latestTime":"05:16 EDT","volume":10,"amount":77.033,"timestamp":1787303768274,"change":-0.0867,"changeRate":-0.01113,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.85,"preClose":7.85,"latestTime":"19:30 EDT","volume":56,"amount":444.14,"timestamp":1787355004937,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.1207398227635308,"impliedVol":1.7131,"impliedVolPercentile":0.898},"requestUrl":"/m/hq/s/AKTX","defaultTab":"news","newsList":[{"id":"1194947881","title":"Akari Therapeutics持续推进AKTX-101新药临床前研究，剑指2027年中启动一期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1194947881","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194947881?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:55","pubTimestamp":1787057708,"startTime":"0","endTime":"0","summary":"Akari Therapeutics正马不停蹄地推进其核心候选药物AKTX-101的IND申报前各项工作。这家生物制药公司明确表示，目标是在2027年年中正式开启一期临床试验。这一时间表的设定，折射出公司对项目推进节奏的明确把控与战略定力。从目前的进展来看，AKTX-101的临床前研究正按部就班地向前推进，为后续的监管申报铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110754433","title":"Akari Therapeutics：AKTX-101在尿路上皮癌临床前模型中展现强劲抗肿瘤活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1110754433","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110754433?lang=zh_cn&edition=full","pubTime":"2026-08-18 20:54","pubTimestamp":1787057652,"startTime":"0","endTime":"0","summary":"Akari Therapeutics近日披露，其核心候选药物AKTX-101在尿路上皮癌临床前研究中显示出显著的抗肿瘤效果。研究数据显示，该药物在多种临床前模型中均表现出强大的肿瘤抑制能力，具体机制或与其靶向补体系统的独特作用模式密切相关。公司方面表示，这一积极结果将支持AKTX-101向临床阶段快速推进，并进一步拓展其在实体瘤适应症中的开发潜力。Akari Therapeutics的管理层强调，他们将持续评估AKTX-101在多癌种中的治疗价值，并加速其临床转化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183937686","title":"Akari Therapeutics 发布2026年第二季度财报，凸显Aktx-101进入一期临床阶段及ADC载荷平台战略合作进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1183937686","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1183937686?lang=zh_cn&edition=full","pubTime":"2026-08-14 04:16","pubTimestamp":1786652208,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC（股票代码：AKTX）公布了其2026年第二季度的财务业绩。同时，公司重点介绍了核心候选药物Aktx-101向一期临床阶段推进的进程，以及在其抗体偶联药物（ADC）载荷平台领域达成的战略合作成果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171020543","title":"Akari Therapeutics与Whitehawk将就Ph1有效载荷开展基于Top1i ADC平台的临床前研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1171020543","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1171020543?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:06","pubTimestamp":1784631970,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC与WhiteHawk宣布，双方将就Ph1有效载荷开展基于Top1i ADC（抗体药物偶联物）平台的临床前研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176996803","title":"Akari Therapeutics任命前AACR主席、著名肿瘤药物开发专家Patricia Lorusso博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1176996803","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176996803?lang=zh_cn&edition=full","pubTime":"2026-07-07 20:57","pubTimestamp":1783429062,"startTime":"0","endTime":"0","summary":"Akari Therapeutics宣布，已任命前美国癌症研究协会主席、在肿瘤药物开发领域享有盛誉的专家Patricia Lorusso博士加入其科学顾问委员会。这一任命旨在借助Lorusso博士深厚的专业知识和行业经验，进一步推动公司在肿瘤治疗领域的研发战略与临床开发进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103366176","title":"Akari Therapeutics：股东拟转售最多600万份ADS，对应4800亿普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1103366176","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103366176?lang=zh_cn&edition=full","pubTime":"2026-07-03 05:24","pubTimestamp":1783027456,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC向美国证券交易委员会（SEC）提交了一份招股说明书补充文件。该文件涉及公司现有股东计划转售最多600万份美国存托凭证（ADS）。根据文件披露，这些ADS代表着高达4800亿股的普通股。本次转售由售股股东发起，公司本身不会从此次交易中获得任何收益。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144680198","title":"Akari Therapeutics 提交文件 拟通过White Lion Capital发行至多250万份ADS","url":"https://stock-news.laohu8.com/highlight/detail?id=1144680198","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144680198?lang=zh_cn&edition=full","pubTime":"2026-06-27 07:12","pubTimestamp":1782515558,"startTime":"0","endTime":"0","summary":"根据一份提交给美国证券交易委员会（SEC）的文件显示，Akari Therapeutics PLC 计划通过White Lion Capital进行证券发售，拟发行最多250万份美国存托凭证（ADS）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199855681","title":"Akari Therapeutics PLC启动Aktx-101的IND支持研究，目标2027年中启动一期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1199855681","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199855681?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:09","pubTimestamp":1779397753,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC宣布，已启动其候选药物Aktx-101的新药临床试验申请（IND）支持性研究。公司目标是在2027年中期之前，推进该药物进入一期临床试验阶段。这一进展标志着Akari在推进其研发管线方面迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169955074","title":"Akari Therapeutics PLC融资款项将分三期拨付，时间跨度为2026年5月27日至7月15日","url":"https://stock-news.laohu8.com/highlight/detail?id=1169955074","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169955074?lang=zh_cn&edition=full","pubTime":"2026-05-21 20:32","pubTimestamp":1779366722,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC宣布，其融资所得款项总额将分三期进行拨付。具体安排如下：首期资金预计于2026年5月27日到位，随后两期将分别在2026年6月和7月15日前完成注入。这一分阶段注资的安排，旨在根据公司研发与运营的阶段性需求，优化资金使用效率，并为后续临床开发及企业活动提供稳定的财务支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149781574","title":"Akari Therapeutics PLC：Aktx-101进入IND支持性研究阶段，一期临床试验预计2026年末/2027年初启动","url":"https://stock-news.laohu8.com/highlight/detail?id=1149781574","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1149781574?lang=zh_cn&edition=full","pubTime":"2026-04-27 20:41","pubTimestamp":1777293688,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC宣布，其研发药物Aktx-101已正式进入IND支持性研究阶段。这一关键进展为后续的临床试验奠定了坚实基础。根据公司规划，该药物的一期临床试验预计将于2026年末至2027年初期间正式启动。\n此举标志着Akari Therapeutics在新药研发领域迈出重要一步。IND支持性研究的顺利推进，将为企业后续向监管机构提交新药临床试验申请提供必要数据支持。整个研发进程正按照既定时间表稳步推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157451809","title":"Akari Therapeutics公布Aktx-101临床前积极数据 展示靶向RNA剪接的同类首创Trop2 ADC有效载荷差异化细胞毒性","url":"https://stock-news.laohu8.com/highlight/detail?id=1157451809","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157451809?lang=zh_cn&edition=full","pubTime":"2026-04-20 20:38","pubTimestamp":1776688695,"startTime":"0","endTime":"0","summary":"Akari Therapeutics公司近日发布其创新药物Aktx-101的临床前研究数据，结果显示该靶向RNA剪接机制的首创型Trop2抗体偶联药物（ADC）有效载荷展现出显著差异化细胞毒性特征。实验数据表明，Aktx-101通过独特作用机制实现对癌细胞的精准杀伤，为ADC药物开发开辟了新方向。这项突破性进展凸显了该候选药物在治疗表达Trop2抗原的恶性肿瘤方面的潜在治疗价值，为后续临床研究奠定重要基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","AKTX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104489368","title":"Akari Therapeutics参与虚拟投资者访谈，探讨与药明合联战略合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1104489368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104489368?lang=zh_cn&edition=full","pubTime":"2026-04-09 20:51","pubTimestamp":1775739103,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC日前参与了题为“这意味着什么”的虚拟投资者访谈活动，重点讨论了该公司与药明合联（WuXi XDC）达成的战略合作伙伴关系。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100548713","title":"Akari Therapeutics任命癌症生物学与RNA领域顶尖专家Prafulla Gokhale博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1100548713","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1100548713?lang=zh_cn&edition=full","pubTime":"2026-02-26 22:16","pubTimestamp":1772115409,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC（简称：Akari）宣布，任命在癌症生物学及RNA研究领域享有盛誉的专家Prafulla Gokhale博士加入其科学顾问委员会。Gokhale博士的加入将为公司在新药研发，尤其是肿瘤治疗方向的战略布局注入重要专业力量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157424138","title":"Akari Therapeutics任命RNA生物学与癌症研究领域全球知名专家Olga Anczukow博士加入科学顾问委员会","url":"https://stock-news.laohu8.com/highlight/detail?id=1157424138","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157424138?lang=zh_cn&edition=full","pubTime":"2026-02-23 21:50","pubTimestamp":1771854616,"startTime":"0","endTime":"0","summary":"Akari Therapeutics PLC（简称：Akari）近日宣布，任命在RNA生物学与癌症研究领域享有国际声誉的专家Olga Anczukow博士加入其科学顾问委员会。这一重要人事任命将进一步强化公司在相关科研领域的专业实力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2517928921","title":"Akari Therapeutics Plc盘中异动 下午盘股价大跌5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517928921","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517928921?lang=zh_cn&edition=full","pubTime":"2025-03-06 02:26","pubTimestamp":1741199186,"startTime":"0","endTime":"0","summary":"北京时间2025年03月06日02时26分，Akari Therapeutics Plc股票出现波动，股价大幅跳水5.57%。截至发稿，该股报0.888美元/股，成交量1.9127万股，换手率0.07%，振幅5.85%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为1.34%。其相关个股中，Chimerix, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 涨幅较大，Silexion Therapeutics Corp、Tc Biopharm  Plc、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为950.74%、305.93%、302.08%，振幅较大的相关个股有Nkgen Biotech, Inc.、Klotho Neurosciences Inc C/Wts 21/06/2029 、Celularity Inc.，振幅分别为82.59%、54.27%、47.22%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022627a2610822&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306022627a2610822&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516320536","title":"Akari Therapeutics Plc股价拉升10.80% 市值涨16万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516320536","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516320536?lang=zh_cn&edition=full","pubTime":"2025-03-03 22:51","pubTimestamp":1741013472,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时51分，Akari Therapeutics Plc股票出现异动，股价大幅拉升10.80%。截至发稿，该股报0.964美元/股，成交量1.1219万股，换手率0.04%，振幅6.78%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.02%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225112a25d45e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303225112a25d45e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","BK4139","LENZ","AKTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514389442","title":"Akari Therapeutics Plc股价拉升14.29% 市值涨53.49万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514389442","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514389442?lang=zh_cn&edition=full","pubTime":"2025-02-27 23:08","pubTimestamp":1740668891,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日23时08分，Akari Therapeutics Plc股票出现波动，股价急速上涨14.29%。截至发稿，该股报1.052美元/股，成交量105股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.80%。其相关个股中，Quoin Pharmaceuticals Ltd、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Pds Biotechnology Corporation涨幅较大，Quoin Pharmaceuticals Ltd、Aeon Biopharma, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为633.35%、104.21%、101.93%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Pds Biotechnology Corporation、Biorestorative Therapies, Inc.，振幅分别为78.88%、35.71%、30.36%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272308119895181f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272308119895181f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AKTX","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856829","title":"Akari Therapeutics Plc股价飙升14.20% 市值涨390.64万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856829","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514856829?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:37","pubTimestamp":1740580623,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时37分，Akari Therapeutics Plc股票出现异动，股价快速上涨14.20%。截至发稿，该股报1.039美元/股，成交量386股，换手率0.00%，振幅0.00%。Akari Therapeutics Plc股票所在的生物技术行业中，整体跌幅为0.40%。其相关个股中，Sab Biotherapeutics Inc C/Wts 22/10/2026 、Immunoprecise Antibodies Ltd.、Channel Therapeutics Corporation涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Immunoprecise Antibodies Ltd.较为活跃，换手率分别为135.54%、100.74%、80.35%，振幅较大的相关个股有Humacyte Inc C/Wts 27/08/2026 、Tevogen Bio Holdings Inc C/Wts 14/02/2029 、Plus Therapeutics, Inc.，振幅分别为38.41%、27.33%、21.29%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223703abddee45&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223703abddee45&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","AKTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514301685","title":"Akari Therapeutics Plc盘中异动 快速下挫6.54%报0.935美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514301685","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514301685?lang=zh_cn&edition=full","pubTime":"2025-02-25 23:31","pubTimestamp":1740497477,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日23时31分，Akari Therapeutics Plc股票出现异动，股价快速下挫6.54%。截至发稿，该股报0.935美元/股，成交量4636股，换手率0.02%，振幅4.50%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.76%。其相关个股中，Organovo Holdings, Inc.、Silexion Therapeutics Corp、Abpro Holdings Inc C/Wts 12/11/2029 涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为1072.13%、964.25%、593.80%，振幅较大的相关个股有Organovo Holdings, Inc.、Adial Pharmaceuticals, Inc、Silexion Therapeutics Corp，振幅分别为121.95%、64.05%、61.16%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523311796300049&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022523311796300049&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","AKTX","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513291168","title":"Akari Therapeutics Plc盘中异动 早盘大幅下挫7.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513291168","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2513291168?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:16","pubTimestamp":1740151010,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时16分，Akari Therapeutics Plc股票出现波动，股价急速跳水7.11%。截至发稿，该股报0.980美元/股，成交量5546股，换手率0.02%，振幅3.32%。Akari Therapeutics Plc股票所在的生物技术行业中，整体涨幅为0.15%。其相关个股中，Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.涨幅较大，Nkgen Biotech, Inc.、Aditxt, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为151.39%、100.24%、82.20%，振幅较大的相关个股有Osr Holdings, Inc.、Osr Holdings Inc C/Wts 09/02/2028 、Nkgen Biotech, Inc.，振幅分别为67.41%、57.50%、44.31%。Akari Therapeutics Plc公司简介：Akari Therapeutics PLC 是一家临床阶段生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231650988de8fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221231650988de8fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AKTX","LENZ","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.akaritx.com","stockEarnings":[{"period":"1week","weight":0.0411},{"period":"1month","weight":-0.1998},{"period":"3month","weight":-0.5703},{"period":"6month","weight":-0.1705},{"period":"1year","weight":-0.7878},{"period":"ytd","weight":-0.3209}],"compareEarnings":[{"period":"1week","weight":-0.0137},{"period":"1month","weight":0.0245},{"period":"3month","weight":0.0269},{"period":"6month","weight":0.1107},{"period":"1year","weight":0.2048},{"period":"ytd","weight":0.1229}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Akari Therapeutics, Plc于2004年10月7日在英格兰和威尔士注册成立。该公司是一家临床阶段的生物技术公司，专注于开发涉及补体成分5（“C5”）和白三烯B4（“LTB4”）通路的自身免疫和炎症性疾病的先进疗法。这些途径中的每一种都在疾病靶向中具有科学上得到充分支持的致病作用。该公司认为，阻断炎症的早期介质将防止引发某些疾病的过程的启动和持续放大。公司自成立以来的活动包括进行研发活动和筹集资金。","yearOnYearQuotes":[{"month":1,"riseRate":0.416667,"avgChangeRate":0.007289},{"month":2,"riseRate":0.25,"avgChangeRate":-0.164819},{"month":3,"riseRate":0.384615,"avgChangeRate":0.051328},{"month":4,"riseRate":0.461538,"avgChangeRate":0.052868},{"month":5,"riseRate":0.230769,"avgChangeRate":0.014482},{"month":6,"riseRate":0.461538,"avgChangeRate":0.016983},{"month":7,"riseRate":0.307692,"avgChangeRate":0.004368},{"month":8,"riseRate":0.461538,"avgChangeRate":0.213456},{"month":9,"riseRate":0.5,"avgChangeRate":0.047326},{"month":10,"riseRate":0.25,"avgChangeRate":-0.130903},{"month":11,"riseRate":0.416667,"avgChangeRate":-0.07207},{"month":12,"riseRate":0.25,"avgChangeRate":-0.096768}],"exchange":"NASDAQ","name":"Akari Therapeutics PLC","nameEN":"Akari Therapeutics PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Akari Therapeutics PLC(AKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Akari Therapeutics PLC,AKTX,Akari Therapeutics PLC股票,Akari Therapeutics PLC股票老虎,Akari Therapeutics PLC股票老虎国际,Akari Therapeutics PLC行情,Akari Therapeutics PLC股票行情,Akari Therapeutics PLC股价,Akari Therapeutics PLC股市,Akari Therapeutics PLC股票价格,Akari Therapeutics PLC股票交易,Akari Therapeutics PLC股票购买,Akari Therapeutics PLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Akari Therapeutics PLC(AKTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Akari Therapeutics PLC(AKTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}